A case of successful desensitization treatment with tepotinib after tepotinib-induced rash

Tepotinib is one of the key drugs for MET exon 14-skipping mutation-positive non-small cell lung cancer (NSCLC). The main adverse event of tepotinib treatment is edema. Rash is a rare adverse event, affecting only 0.7% of patients. We report a case of successful desensitization after skin rash cause...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Tomoki, Hata, Sakura, Baba, Takahiro, Koyanagi, Taisaku, Umeno, Takahiro, Nishii, Kazuya, Kuyama, Shoichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495622/
https://www.ncbi.nlm.nih.gov/pubmed/37706029
http://dx.doi.org/10.1016/j.rmcr.2023.101911

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10495622/
https://www.ncbi.nlm.nih.gov/pubmed/37706029
http://dx.doi.org/10.1016/j.rmcr.2023.101911

Ejemplares similares